Global elimination of mother-tochild transmission of HIV and syphilis

Teodora Elvira Wi

Medical Officer


Twitter @HRPresearch







WHO estimates 394 million new cases of four curable STIs in 15-49 years olds in 2012




Curable STIs: chlamydia, gonorrhea, syphilis, trichomoniasis


Source: WHO. Global incidence and prevalence of selected curable sexually transmitted infections - 2012.



Prevalence in Adults (%): Based on 2005-2012 data



Incident cases per 1000 in 2012: Adults 15 to 49



Mother-to-child transmission of HIV and syphilis

MTCT transmission:

HIV: around 1/3 (15-45%)

Syphilis: >1/2 (52-90%,


depending on maternal stage)

Without treatment:

HIV: ~1/3 with HIV die <12 mos ~1/2 die by <24 mos

Syphilis: 52% adverse outcome in pregnancy

Untreated active syphilis





Preventable Burden



Burden

HIV: estimated 240,000 MTCT infections in 2013

Syphilis: estimated 350,000 adverse outcomes in 2012 (including 143,000 perinatal deaths)

Interventions exist

HIV: early and continued ART can reduce transmission from 15-45% <2% or <5%

Syphilis: Screening and treatment of syphilis-infected mothers < 30 days before delivery can prevent perinatal morbidity and mortality

Target pregnant women and similar control measures



For HIV as for Syphilis

Elimination of MTCT of HIV and syphilis




Decrease prevalence of HIV+ and syphilis + in pregnant women and their partners

Control of HIV and syphilis in general population and in high risk group

Proportion of countries reporting a national EMTCT strategy in place, by region, 2014


WHO Region	% (no.) of countries with strategy for EMTCT of syphilis	Number of countries reporting in 2014
African Region	45% (18)	40
Region of the Americas	89% (25)	28
Eastern Mediterranean	50% (6)	12
Region		
European Region	50% (13)	26
South-East Asia Region	70% (7)	10
Western Pacific Region	64% (7)	11
Overall	60% (76)	127 STI Surveillance Report 2015

Estimated HIV testing and counselling coverage among pregnant women in LMIC by WHO region, 2005 and 2009-2012



Source: 2013 Global AIDS Response Progress Reporting (WHO/UNICEF/UNAIDS), United Nations Department of Economic and Social Affairs, Population Division (2013). World Population Prospects: The 2012 Revision.

Number of pregnant women living with HIV in LMIC and number and percentage of those women receiving ARV drugs for PMTCT of HIV, 2005-2013





Single-dose nevirapine is included in the data for 2005 to 2009.

Sources: Global AIDS Response Progress Reporting (WHO/UNICEF/UNAIDS) and validation process for the number of pregnant women living with HIV receiving ARV drugs for PMTCT, and UNAIDS 2013 estimates for the number of pregnant women living with HIV.

Declining seroprevalence of syphilis in India

57% reduction in new HIV infections (2000-11) with scale-up of prevention strategies





Source: routine programme reporting

Proportion of pregnant women in antenatal care (ANC)

region	, 2008	(or	2010),	2012	and 2	2014	Global STI Surveillance Re	eport 2015
			_	_	_			

who were tested for syphilis, who tested positive by WHO region, 2008 (or 2010), 2012 and 2014 Global STI Surveillance Report 2015												
	Percentage of ANC attendees tested for syphilis who were positive for syphilis											
	2008 2012 2			20	14	20	08	20	12	203	14	
WHO region	No. reporting	Median	No.	Median	No. reporting	Median	No. reporting	Median	No. reporting	Median	No. reporting	Median value

countries

34

19

5

9

7

15

89

value (%)

71.8

82.6

93.1

37.4

98.3

86.1

countries

21

17

0

6

7

10

61

value(%)

58.5

73.0

100

78

countries

18

14

3

9

3

4

51

African

Region Region of

Americas Eastern

Mediterrane

an Region European

Region South-East

Pacific

Region

Asia Region Western

Globial @H

the

	for syphilis		who wer	e positive for	syphilis
Percentage	of ANC atten	dees tested	Percentage of ANC attendees teste		
			Global	SITSurveillance	e Report 201

value (%)

40.1

87.5

42.6

93.4

58.3

100

85.5

value (%)

2.3

0.9

0.3

1.3

0.3

1.4

countries

30

14

4

9

6

8

71

value (%)

1.9

0.5

0.1

2.0

1.0

(%)

1.6

0.4

0

0.1

0.5

1.8

countries

31

21

4

9

7

13

85

countries

22

18

2

7


4

11

64

who w	vere tested for syphilis, who	tested positive by WHC
region	, 2008 (or 2010), 2012 and 2	Global STI Surveillance Report
	Percentage of ANC attendeds tested	Percentage of ANC attendeds to

Percentage of ANC women positive for syphilis, 2015



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization Map Production: Health Statistics and Information Systems (HSI) World Health Organization



© WHO 2015. All rights reserved.



Proportion of pregnant women in antenatal care (ANC)

region, 2008 (or 2010), 2012 and	2014 Global STI Surveillance Report 2015
Percentage of ANC attendees tested	Percentage of syphilis-positive ANC
who were positive for syphilis	attendees who received treatment

Median

value

(%)

1.6

0.4

0

0.1

0.5

1.8

0.7

2010

Median

value

(%)

100

85

98

99

No.

reporting

countries

15

16

0

3

3

7

44

2012

Median

value

(%)

100

80.5

93.0

94

No.

reporting

countries

13

13

0

4

4

9

43

2014

No.

reporting

countries

21

19

3

7

6

11

67

Median

value

(%)

98.0

92.9

80.0

100

89.9

100

96

Percentage of ANC attendees tested	Percentage of syphilis-positive ANC
region, 2008 (or 2010), 2012 and	2014 Global STI Surveillance Report 201
who tested positive and who re-	ceived treatment by WHO

who tested positive ar	nd who received treati	ment by WHO
region, 2008 (or 2010)	, 2012 and 2014 Global ST	I Surveillance Report 20

who tested positi	re and who received treatment by WHO
region, 2008 (or 2	010), 2012 and 2014 Global STI Surveillance Report 20

who tested positive and who received treatment by	WHO
region, 2008 (or 2010), 2012 and 2014 Global STI Surveillance	e Report 2

2014

No.

reporting

countries

31

21

4

9

7

13

85

2008

Median

value

(%)

2.3

0.9

0.3

1.3

0.3

1.4

No.

reporting

countries

30

14

4

9

6

8

71

WHO region

African Region

Region of the

Mediterranea

Americas Eastern

n Region European

Region South-East

Asia Region Western

Pacific Region

1 / Twitter @HR

Global

2012

Median

value

(%)

1.9

0.5

0.1

2.0

1.0

No.

reporting

countries

22

18

2

7

4

11


64

who tested positive and who received treatment by WHO
region, 2008 (or 2010), 2012 and 2014 Global STI Surveillance Report 2

Global Guidance for EMTCT Validation

- Standardized Criteria
- Process
- Secretariat

- WHO, UNAIDS, UNICEF, UNFPA
- Based on country pilots
- Common systematic approach for dual elimination







15

Criteria for elimination of mother-to-child transmission of HIV and syphilis

	ELIMINATION	
	HIV	Syphilis
IMPACT	• MTCT < 2% OR < 5% in BF	• Case rate ≤ 50 per
criteria	populations	100 000 live births
	• Case rate ≤ 50 per 100 000	
	live births	
PROCESS	• ANC1 coverage ≥ 95%	• ANC1 coverage ≥ 95%
criteria	• Testing coverage ≥ 95%	• Testing coverage ≥ 95%
	• ART coverage ≥90%	Treatment coverage
		>95%

Global surveillance definition of congenital syphilis

- still birth, live birth or a fetal loss at greater than 20 weeks of gestation or more than 500 grams to a syphilis seropositive mother without adequate syphilis treatment; or
- stillbirth, live birth or child under 2 years of age with microbiological evidence of syphilis infection.
 - demonstration by dark-field microscopy or fluorescent antibody detection of T. pallidum in the umbilical cord, the placenta, nasal discharge or skin lesion materials;
 - detection of T. pallidum-specific IGM,
 - infant with a positive non-treponemal serology titre ≥
 fourfold higher than the mother's titre.

Qualifying Requirements for EMTCT Validation

- National EMTCT validation indicators
 - Process indicator targets achieved for <u>2 years AND</u>
 - Impact indicator targets achieved for 1 or more years*.
- Review of equity considerations, e.g.
 - Low performance district or high burden area
 - Key populations and other vulnerable groups
- Robust national monitoring and surveillance system
- Basic Human Rights Considerations must be met



Process of EMTCT validation

National
Validation
Committee
(NVC)

• Collects, reviews and decides on the national documentation through consultations

E A M Regional


 Reviews country reports and country surveillance system comply with global minimum validation standard and regional standards

NVT and RVT:
data collection
and analysis,
in-country
visits.

Global Validation Committee (GVC) • Reviews country/RVC reports to ensure consistency and compliance with the minimum global criteria.



WHO announces Cuba as the first country to eliminate MTCT of HIV and syphilis (June 30, 2015)



Cuba is first country to eliminate mother to child HIV transmission

Cuba: defeating AIDS and advancing global health Editorial www.thelancet.com Vol 386 July 11, 2015

EL@MUNDO

Cuba, primer país del mundo en eliminar la transmisión del VIH de madre a hijo



¿Cómo se convirtió Cuba en el primer país en eliminar la transmisión del VIH de madre a hijo?

EL PAIS

Cuba named first country to end mother-tochild HIV transmission


Cuba es el primer país en eliminar la transmisión de madre a hijo del VIH





BBC

Since Cuba, many countries in Asia, Europe and South America are close to being validated for EMTCT of HIV



Benzathine Penicillin (BPG) shortages

- □ Benzathine PCN 2.4 M units x 1
- Alternative Treatment
 - Procaine PCN 1.2 M unit IN x 10-14 days
 - Doxycycline 100 mg 2 x day for 14 days
 - Ceftriaxone 1 gram x 1 for 10-14 days
 - Azithromycin 2 grams
- No other viable treatment indicated for syphilis treatment in pregnant women
 - Doxycycline is contraindicated during pregnancy
 - Azithromycin and Erythromycin may result to adverse birth outcomes
 - Ceftriaxone crosses the placenta but optimal dose/duration for pregnant women is unknown



Stock outs in 2015	No reported shortage	Did not respond
Brazil	Anguilla	Antigua and Barbuda
	Argentina	Bahamas
Jamaica	Belize	Barbados
Panama	Bolivia	Bermuda
	Colombia	Cayman Islands
Suriname	Costa Rica	Chile
Trinidad and	Cuba	Dominica
	Dominican Republic	Ecuador
Tobago	El Salvador	French Guyana
	Grenada	Guadelupe
	Guatemala	Martinique
	Guyana	St. Kitts and Nevis
	Haiti	Turks and Caicos Islands
	Honduras	
	Mexico	
	Montserrat	
	Nicaragua	
	Paraguay	
	Peru	
	St. Lucia	
	St. Vincent and the Grenadines	
	Uruguay	
	Venezuela	

Estimating Benzathine Penicillin Need for the Treatment of Pregnant Women Diagnosed with Syphilis during Antenatal **Care in High-Morbidity Countries**

- Total number of women requiring treatment in 30 countries = 351,016.
- Syphilis screening coverage at or above 95% for 30 countries, number of women requiring treatment = 712,089.
- □ Live-born infants of mothers who test positive and are treated for syphilis in pregnancy = 351,016 doses of weight-based benzathine penicillin
- 95,938 adverse birth outcomes would be prevented including 37,822 stillbirths, 15,814 neonatal deaths, and 34,088 other congenital syphilis cases



Next steps

- Finalize guidelines
- Address Benzathine PCN shortage
- Support countries to obtain validation of EMTCT or for pre validation status
- Research on new treatment options for syphilis





Acknowledgements

Nathalie Broutet Shaffiq Essajee Chika Hayashi Maura Laverty Lori Newman Stephen Nurse-Findley Melanie Taylor

For more information:

www.who.int/reproductivehealth/topics/rtis/syphilis/en/index.html

http://www.who.int/hiv/pub/emtct-validation-guidance/en/

